ReviewTzu chi medical journal
Precision bacteriophage therapy for multidrug-resistant recurrent urinary tract infections: From biological rationale to clinical translation in Taiwan.
Review in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent urinary tract infections (rUTIs), driven by multidrug-resistant (MDR) uropathogens, intracellular reservoirs, and biofilms, progressively circumvent conventional antibiotic therapy. Bacteriophage (phage) therapy has re-emerged as a precision medicine strategy offering narrow host specificity, self-amplification at the infection site, and intrinsic antibiofilm activity via depolymerases. This minireview evaluates the biological rationale and translational evidence for phage therapy in MDR-rUTIs, emphasizing the clinical distinction between standardized trials for acute uncomplicated infections and personalized salvage interventions for complex rUTIs. Clinical data suggest that personalized, susceptibility-matched phage regimens have demonstrated encouraging clinical outcomes in reported cases; however, these findings are primarily based on case reports and small observational series, necessitating further validation through large-scale randomized controlled trials. In Taiwan, where extended-spectrum β-lactamase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.